Veoza Approved for Use in England
Veoza (fezolinetant) has been officially approved for use on the NHS to prevent hot flushes in menopausal women, marking a significant advancement in treatment options. This new drug is expected to benefit around 500,000 women in England, particularly those for whom hormone replacement therapy (HRT) is unsuitable.
Impact of Hot Flushes
Hot flushes affect approximately 70% of women experiencing menopause, leading to considerable discomfort and disruption in daily life. Helen Knight, a representative from NICE, stated, “We know that menopausal hot flushes and night sweats can have a profound impact on quality of life and significantly affect overall wellbeing.” This highlights the urgent need for effective treatments.
How Veoza Works
Veoza is designed as a once-daily oral tablet that operates by blocking nerve pathways in the brain responsible for triggering hot flushes and night sweats. This mechanism offers a new approach to managing symptoms that have long been challenging for many women.
Cost and Accessibility
The NHS list price for Veoza is set at £44.80 per 28-tablet pack, which NICE has deemed cost-effective and valuable for taxpayers. This approval is particularly significant given the historical lack of safe and effective treatment options for menopausal symptoms.
Expert Opinions
Dr. Sue Mann expressed optimism about the approval, stating, “Symptoms of menopause including hot flushes and night sweats can affect every part of a woman’s life, so this is very welcome news especially for women who are unable to or don’t wish to take hormone replacement therapy.” She added that Veoza represents another vital treatment option that could help hundreds of thousands of women manage their symptoms more effectively.
Future Expectations
With the approval of Veoza, healthcare professionals and patients alike are hopeful for improved quality of life for those suffering from menopausal symptoms. The introduction of this treatment is expected to provide much-needed relief, especially for women who have struggled with inadequate options in the past.
As the healthcare community prepares for the rollout of Veoza, details remain unconfirmed regarding its availability and distribution across the NHS. Nevertheless, the approval of this drug marks a pivotal moment in the ongoing conversation about women’s health and menopause management.
